Immunic Study (Industry Sponsored) - Wesley Research Institute
Wesley Research Institute
Donate
Now

This clinical trial will investigate a potential treatment option for coeliac disease. This could potentially improve quality of life for people with coeliac disease.

Research Objectives

Status

Completed

Recruitment

Closed

Patient Group

Patients with positive coeliac disease biopsy

Study location

Wesley Research Institute

Study type

Industry Sponsored
Sponsors: Immunic Australia

Lead investigator

  • Dr James Daveson

Clinical trial coordinator

  • Emma Brownrigg

Technical title

A three-part double blind, placebo controlled Phase 1 B of IMU-856 in healthy volunteers and patients with coeliac disease

About this research project

This clinical trial will investigate a potential treatment option for coeliac disease. The only effective treatment currently available for coeliac disease is a strict, lifelong, gluten-free diet. With gluten being present in a variety of food and drinks, this study brings hope to people suffering with this disease. This study will assess the safety and tolerability of a potential new oral treatment (IMU-856) when given to people with coeliac disease. This treatment works by blocking a protein found in the gut, which is believed to play an important role in strengthening the delicate lining of the gut in order to prevent damage that might cause an inflammatory reaction. This could potentially improve quality of life for people with coeliac disease.

Our goals:

  • Research into faster and more accurate diagnosis
  • Improve understanding around the causes of disease and better prediction of disease progression
  • Increase survival and quality of life for patients and families

 

Latest News

Jillian’s Story

This was my first experience at being involved in any sort of research. If I get the opportunity again, I would definitely put my hand up after the wonderful experience I had with your team. Thank you so much to Emma and all your team for making me feel so welcome.    Jillian Meet Jillian, retired […]

Breaking Ground in Paediatric Rare Disease Research

Wesley Research Institute is home to a groundbreaking trial using triheptanoin, a dietary fat, to treat Ataxia-Telangiectasia (A-T), a rare degenerative neurological disorder. This trial has shown promising results, with observed improvements in neurology scales and cellular biomarkers indicating the treatment’s effectiveness.

World-First ‘Back to the Future’ Research Set To Boost Pandemic Protection  

A world-first research project by two Queensland professors is set to offer a blueprint for developing more effective vaccines and therapies specifically tailored to safeguard the health of children and young adults in times of global health crises.  Spearheaded by Professor John Fraser, Dr Arutha Kulasinghe and Associate Professor Kirsty Short, this pioneering study, funded […]
1 2 3 12
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram